Bimagrumab is a monoclonal antibody commercialized by Eli Lilly and Co, with a leading Phase II program in Obesity. According to Globaldata, it is involved in 17 clinical trials, of which 14 were completed, 1 is ongoing, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Bimagrumab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Bimagrumab is expected to reach an annual total of $16 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Bimagrumab Overview

Bimagrumab (BYM-338) is under development for the treatment of non-diabetic patients with obesity. Bimagrumab is administered as an intravenous infusion. It is a fully human HuCAL-based antibody which targets ActRIIB (activin receptor type-2B). It was also under development for cachexia in patients with chronic obstructive pulmonary disorder, type 2 diabtetes, stage IV non-small cell lung cancer or stage III/IV adenocarcinoma of the pancreas, musculoskeletal diseases such as sporadic inclusion body myositis (sIBM), hip fracture, sarcopenia, disuse muscle atrophy associated with femoral fracture, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF) and unspecified indications.

Eli Lilly and Co Overview

Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops, and markets human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, autoimmune disorders, men’s health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company operates R&D facilities, and production and distribution facilities in North America, South America, Europe, the Middle East, Africa and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
The company reported revenues of (US Dollars) US$34,124.1 million for the fiscal year ended December 2023 (FY2023), an increase of 19.6% over FY2022. In FY2023, the company’s operating margin was 18.9%, compared to an operating margin of 25% in FY2022. In FY2023, the company recorded a net margin of 15.4%, compared to a net margin of 21.9% in FY2022. The company reported revenues of US$8,768 million for the first quarter ended March 2024, a decrease of 6.3% over the previous quarter.

For a complete picture of Bimagrumab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.